A surge in demand for menopausal hormone replacement therapy has led to prescription shortages following the FDA's removal of its most serious safety warnings from HRT products. This causal chain is confirmed by Fox News, NPR, the FDA's own press release, Nature, and the AJMC.
In November 2025, HHS and the FDA announced removal of 'black box' warnings from HRT products — warnings in place for over two decades cautioning about cardiovascular disease, breast cancer, and dementia risks. Label changes took effect in February 2026.
FDA Commissioner Dr. Marty Makary said the move is 'backed by decades of research' and that clinical trials 'do not support earlier fears linking HRT to higher breast cancer mortality.' HHS Secretary Robert F. Kennedy Jr. said the old labels were 'designed to frighten women and to silence doctors.' Both statements were carried by Fox News and NPR.
The consequences were swift. NPR documented a 'mad scramble' to fill prescriptions. CVS confirmed to NPR that manufacturers can't supply sufficient estrogen products. Fox affiliate KTVU reported the same shortages in the Bay Area.
The medical community remains divided. Nature published analysis noting the label change has 'triggered debate.' Research shows HRT is safe for women under 60 or within 10 years of menopause, but risks may increase for older women or long-term use.
Left-Leaning Emphasis
- NPR focuses on patients struggling to fill prescriptions and the public health impact of sudden shortages.
- Nature and medical journals raise concerns about whether the science fully supports removing all warnings.
Right-Leaning Emphasis
- Fox News frames the removal as the Trump administration 'advancing women's health.'
- Conservative coverage highlights RFK Jr.'s criticism that the old warnings were based on 'misinterpreted data.'
Sources
- Fox News Feb 26
- NPR Mar 10
- FDA (Official) Feb 26
- Nature Mar 8